We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
-10.62%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$2.76B
AUM Growth
-$25.9M
Cap. Flow
+$49.6M
Cap. Flow %
1.8%
Top 10 Hldgs %
58.38%
Holding
114
New
31
Increased
18
Reduced
24
Closed
20

Top Buys

Rank Stock Value
1
C icon
Citigroup
C
+$14.9M
2
DG icon
Dollar General
DG
+$14.5M
3
MJN
Mead Johnson Nutrition Company
MJN
+$12.2M
4
APTV icon
Aptiv
APTV
+$9.58M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$9.21M

Top Sells

Rank Stock Value
1
ACOR
Acorda Therapeutics
ACOR
+$11.8M
2
GS icon
Goldman Sachs
GS
+$8.41M
3
CCI icon
Crown Castle
CCI
+$7.34M
4
XOMA
Xoma
XOMA
+$7.26M
5
FURX
FURIEX PHARMACEUTICALS INC COM STK (DE)
FURX
+$5.55M

Sector Composition

Rank Sector Weight
1 Miscellaneous 52.76%
2 Consumer Discretionary 22.6%
3 Healthcare 22.19%
4 Consumer Staples 1.28%
5 Financials 0.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HOUS
101
CALL
DELISTED
Anywhere Real Estate
HOUS
– –
-100,000
Closed -$4.95M
LEG
102
CALL
DELISTED
Leggett & Platt
LEG
– –
-100,000
Closed -$3.09M
MAS icon
103
CALL
Masco
MAS
$13.5B
– –
-512,100
Closed -$10.2M
MDLZ icon
104
CALL
Mondelez International
MDLZ
$79.7B
– –
-200,000
Closed -$7.06M
NG icon
105
NovaGold Resources
NG
$3.17B
– –
-1,000,000
Closed -$3.41M
UAL icon
106
CALL
United Airlines
UAL
$35.4B
– –
-400,000
Closed -$15.1M
VMC icon
107
CALL
Vulcan Materials
VMC
$32.7B
– –
-300,000
Closed -$17.8M
VNDA icon
108
CALL
Vanda Pharmaceuticals
VNDA
$311M
– –
-100,000
Closed -$1.24M
VNDA icon
109
Vanda Pharmaceuticals
VNDA
$311M
– –
-150,000
Closed -$1.86M
XBI icon
110
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.6B
– –
-450,000
Closed -$19.5M
ONIT
111
Onity Group
ONIT
$286M
– –
-5,000
Closed -$3.24M
SPWR
112
DELISTED
SunPower Corporation Common Stock
SPWR
– –
-152,700
Closed -$2.98M
SGEN
113
CALL
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-100,000
Closed -$3.99M
ESRX
114
CALL
DELISTED
Express Scripts Holding Company
ESRX
– –
-100,000
Closed -$7.02M
1 2 3 4
5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q1 2014 Portfolio in Review

As of Q1 2014, Artal Group held 114 positions worth $2.76B, down 0.93% from $2.79B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Artal Group's Q1 2014 filing shows 31 new, 18 increased, 24 reduced and 20 closed positions. Its largest new stake was Citigroup: 300,000 shares worth $14.3M. The largest sale was Acorda Therapeutics, an estimated $11.8M.

By sector, the portfolio is most concentrated in Miscellaneous at 53% of assets, up from 42% a quarter earlier, followed by Consumer Discretionary and Healthcare.

  • Artal Group's largest Q1 2014 buy was Citigroup: 300,000 shares worth $14.3M.
  • Artal Group added most to BioMarin Pharmaceuticals in Q1 2014, an estimated $9.21M increase.
  • Artal Group's biggest Q1 2014 reduction was Acorda Therapeutics, cutting an estimated $11.8M.
  • Artal Group fully exited Goldman Sachs in Q1 2014, selling an estimated $8.41M.
  • Artal Group's ten largest holdings make up 58% of its $2.76B portfolio in Q1 2014.
  • Artal Group opened 31 new positions and closed 20 in Q1 2014.
  • Artal Group's portfolio value fell 0.93% quarter-over-quarter to $2.76B.

Based on Artal Group's 13F filing for Q1 2014, filed 15 May 2014.